The release of the 750mcg teriparatide formulation in Australia has seen controlled availability to date. Primarily designated for patients with severe skeletal fragility who have not responded to other medications, access is carefully managed. Existing supply levels are constrained , and individuals should verify regarding their specialist the … Read More